期刊文献+

伏立康唑所致精神异常与其血浆谷浓度的相关性探讨 被引量:22

Discussion of the Correlation between Voriconazole's Trough Concentration and Mental Abnormity Rate
原文传递
导出
摘要 目的研究伏立康唑致精神异常发生率与血浆谷浓度的关系。方法回顾性分析中南大学湘雅医院2016年5月~2017年5月监测的151名患者伏立康唑血浆谷浓度与精神异常的发生情况。结果 151例患者中,多梦的总体发生率为21.85%,Logistic二项回归分析结果表明,多梦与血浆谷浓度成正相关(P=0.02)。幻觉的总体发生率为15.23%,Logistic二项回归分析结果表明,幻觉与血浆谷浓度成显著正相关(P=0.002)。结论伏立康唑致精神异常发生率与血浆谷浓度有良好相关性。 OBJECTIVE To explore the correlation between voriconazole's trough concentration and mental abnormity. METH- ODS Retrospectively analyze voriconazole's trough concentration and the occurrence of mental abnormity in 151 patients from May 2016 to May 2017 in Xiangya Hospital. RESULTS In 151 patients, Insomnia rate is 21.85%, binary logistic regression analysis showd that the insomnia rate is positively related to voriconazole's trough concentration (P = 0. 02). Illusion rate is 15.23%, binary lo- gistic regression analysis showd that the illusion rate is positively related to voriconazole' s trough concentration ( P = 0. 002 ) . CONCLUSION There is a significant correlation between voriconazole's mental abnormity and trough concentration.
作者 戴婷婷 胡林 李逃明 唐勇军 DAI Ting-ting;HU Lina;LI Tao-minga;TANG Yong-junb(a. Department of Pharmac;b. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, Chin)
出处 《中国药学杂志》 CAS CSCD 北大核心 2018年第5期375-378,共4页 Chinese Pharmaceutical Journal
关键词 伏立康唑 精神异常 药物不良反应 谷浓度 voriconazole mental abnormity adverse drug reaction trough concentration
  • 相关文献

参考文献2

二级参考文献36

  • 1曹永兵,张磊,王彦,姜远英.伏立康唑及其临床应用[J].中国新药与临床杂志,2005,24(4):330-332. 被引量:48
  • 2何礼贤.呼吸病学[M].北京:人民卫生出版社,2003,756-776.
  • 3Zonios DI,Gea-Banacloche J,Childs R,et al.Hallucinations during voriconazole therapy[J].Clin Infect Dis,2008,47(1):e7-e10.
  • 4Pascual A,Calandra T,Bolay S,et al.Voriconazole therapeutic drug monitoring in patients with invasive mycoses impr oves efficacy and safety outcomes[J].Clin Infect Dis,2008,46(2):201-211.
  • 5Jeu L,Piacenti FJ,Lyakhovetskiy AG,et al.Voriconazole[J].Clin Ther,2003,25(5):1321-1381.
  • 6Levêque D,Nivoix Y,Jehl F,et al.Clinical pharmacokinetics of voriconazole[J].Int J Antimicrob Agents,2006,27(4):274-284.
  • 7Tsiodras S,Zafiropoulou R,Kanta E,et al.Painful peripheral neuropathy associated withvoriconazole use[J].Arch Neurol,2005,62(1):144-146.
  • 8Johnson LB,Kauffman CA.Voriconazole:a new triazole antifungal agent[J].Clin Infect Dis,2003,36(5):630-637.
  • 9Kadikoy H,BarkmeierA,Peck B,et a1.Persistent photopsia following course of oral voriconazole[J].J Ocul Pharmacol Ther,2010,26(4):387-388.
  • 10EidenC,PeyrèireH,CociglioM,et al.Adverse effects of voriconazole:analysis of the French Pharmacovigilance Database[J].Ann Pharmacother,2007,41(5):755-763.

共引文献40

同被引文献129

引证文献22

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部